The Phenomenon of Anti-Drug Antibodies in Psoriasis: Mechanisms, Clinical Impact, and Therapeutic Strategies

TL;DR

This paper explores how antibodies against psoriasis treatments can reduce their effectiveness and highlights the need for biomarkers to personalize therapy.

Contribution

The paper provides insights into the mechanisms and clinical impact of anti-drug antibodies in psoriasis treatment.

Findings

Anti-drug antibodies can lead to reduced efficacy of biologic treatments in psoriasis.

Immune responses range from clinically insignificant to causing significant treatment failure.

Identifying predictive biomarkers could help personalize and optimize treatment strategies.

Abstract

Biological drugs have revolutionized the treatment of many chronic diseases, starting with cancer. They normally consist of antibodies that are also effectively used to treat several autoimmune diseases, including psoriasis. These products, called biologics, work by selectively blocking the activity of certain targets, mainly cytokines, which play a crucial role in the pathogenic and inflammatory processes involved in a particular disease. Unfortunately, a reduction in response to these biological treatments may occur over time, and this phenomenon is often due to the development of antibodies against the therapeutic antibodies. The immune responses directed to these therapeutics range from transient anti-drug antibodies (ADA) formation, with no clinical significance, to the generation of high titers and persistence of ADA, causing loss of efficacy. Considering the costs associated with the use of biological drugs, there is growing interest in identifying biomarkers that can predict clinical response to personalize treatments.

Figures